Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anne Teremi

Physician Assistant, Medical Okemos, MI Physician Assistant

NPI 1831278092 CMS profile 10739360

2375 Woodlake Dr Ste 300, Okemos, MI 48864

Open in the dashboard

General payments

$11,531

704 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anne Teremi of Okemos, MI is reported in the CMS Open Payments database as having received $11,531 across 704 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,823 160
2024 General $2,396 158
2023 General $2,439 145
2022 General $2,071 119
2021 General $1,803 122

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anne Teremi
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Anne Teremi were reported at $2,823. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Anne Teremi Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,803 $156 $41–$563 $132
2022 $2,071 $185 $55–$649 $149
2023 $2,439 $199 $58–$717 $160
2024 $2,396 $206 $62–$740 $164
2025 $2,823 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $2,030 128 payments
  2. UCB, Inc. $1,610 94 payments
  3. Janssen Biotech, Inc. $1,590 112 payments
  4. AbbVie, Inc. $1,324 98 payments
  5. AstraZeneca Pharmaceuticals LP $753 39 payments
  6. Novartis Pharmaceuticals Corporation $698 41 payments
  7. Pfizer Inc. $606 39 payments
  8. E.R. Squibb & Sons, L.L.C. $514 27 payments
  9. Lilly USA, LLC $291 15 payments
  10. Genentech USA, Inc. $244 14 payments
  11. Other $1,872 97 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,232 698 payments
  2. Education $299 6 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,585 109 payments
  2. Cimzia $1,193 71 payments
  3. RINVOQ $1,158 89 payments
  4. SAPHNELO $716 37 payments
  5. Otezla $662 41 payments
  6. Enbrel Inflammation $654 39 payments
  7. COSENTYX $554 33 payments
  8. Enbrel Inflammation $519 32 payments
  9. ORENCIA $494 26 payments
  10. XELJANZ $476 30 payments
  11. Other $5,722 361 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,778

Median for Physician Assistant: 241

Drug cost

$2,737,047

Median for Physician Assistant: $4,110

Branded share of claims

45.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Etanercept Brand 70 $509,672
Humira(Cf) Adalimumab Brand 56 $426,624
Orencia Clickject Abatacept Brand 37 $214,047
Enbrel Sureclick Etanercept Brand 28 $212,508
Humira Pen Adalimumab Brand 25 $195,651
Rinvoq Upadacitinib Brand 27 $182,520
Cosentyx Sensoready Pen Secukinumab Brand 22 $150,161
Cosentyx (2 Syringes) Secukinumab Brand 19 $141,161
Orencia Abatacept Brand 25 $140,207
Humira(Cf) Pen Adalimumab Brand 20 $138,391

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Cimzia
  • UCB, Inc. $321
$321 21 —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $260
$260 — —
RINVOQ
  • AbbVie, Inc. $223
$223 27 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $216
$216 60 —
Bimzelx
  • UCB, Inc. $152
$152 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

704 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record